You have 9 free searches left this month | to do more

fedratinib

Fedratinib is a drug used to treat Healthy Volunteers, Primary Myelofibrosis, Myelofibrosis, and other conditions. Fedratinib is being actively studied in 8 studies and prior, has been studied in 3.

Top SponsorsTop SitesTop Investigators
CelgenePPD Phase 1 Clinic
Bristol-Myers SquibbA.O.U. di Bologna Policlinico S.Orsola-Malpighi
University of ChicagoASST Spedali Civili P.O. di Brescia
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
B
A Study to Evaluate the Bioavailability of Fedratinib When Administered in Different Ways to Healthy Adult Participants
Not yet recruiting
  • Healthy Volunteers
  • Fedratinib
  • (no location specified)
2021-09-16
Sep 16, 2021
C
A Study to Evaluate the Effect of a Dual CYP2C19 and CYP3A4 Inhibitor, Fluconazole, on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects - 2021
Completed
  • Healthy Volunteers
  • Austin, Texas
    PPD Phase 1 Clinic
2021-11-17
Nov 17, 2021
U
A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
Recruiting
  • IDH Mutation
  • +4 more
  • Chicago, Illinois
    University of Chicago Medical Center
2021-11-12
Nov 12, 2021
C
A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment
Recruiting
  • Healthy Volunteers
  • Hepatic Impairment
  • Fedratinib
  • Miami, Florida
  • +2 more
2020-12-02
Dec 2, 2020
C
Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects - 2019
Completed
  • Healthy Volunteers
  • Fedratinib
  • +2 more
  • Dallas, Texas
    Covance Clinical Research Unit Inc - Dallas
2020-08-19
Aug 19, 2020
U
Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
Recruiting
  • Acute Myeloid Leukemia
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2021-08-27
Aug 27, 2021
B
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
Recruiting
  • Myelofibrosis
  • La Jolla, California
  • +25 more
2022-01-04
Jan 4, 2022
C
Influence of Fedratinib on the Pharmacokinetics of the Transporter Probe Substrates Digoxin, Rosuvastatin, and Metformin - 2020
Completed
  • Healthy Volunteers
  • Fedratinib
  • +3 more
  • Austin, Texas
    PPD Phase 1 Clinic
2020-05-20
May 20, 2020
C
A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Recruiting
  • Primary Myelofibrosis
  • Fedratinib
  • Aomori, Japan
  • +15 more
2021-07-21
Jul 21, 2021
C
A Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib With Concomitant Luspatercept for Subjects With Anemia
Recruiting
  • Primary Myelofibrosis
  • +2 more
  • Aurora, Colorado
  • +34 more
2021-08-19
Aug 19, 2021
C
An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
Recruiting
  • Primary Myelofibrosis
  • +2 more
  • FEDRATINIB
  • Best Available Therapy (BAT)
  • Darlinghurst, New South Wales, Australia
  • +109 more
2021-09-21
Sep 21, 2021